1-3 of 3
Judy Sutherland, MD
Close
Sort by
Journal Articles

Outcome in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with CHOP-R Can Be Predicted by Stage and Serum Lactate Dehydrogenase (LDH) Level.

Laurie H. Sehn, MD, MPH, Mukesh Chhanabhai, MD, Karamjit Gill, MD, Paul Hoskins, MD, Richard Klasa, MD, Kerry J. Savage, MD, Tamara Shenkier, MD, Judy Sutherland, MD, Randy D. Gascoyne, MD, Joseph M. Connors, MD
Journal: Blood
Blood (2006) 108 (11): 2739.
https://doi.org/10.1182/blood.V108.11.2739.2739
Published: 2006
Journal Articles

Revised International Prognostic Index (R-IPI) Is a Better Predictor of Outcome Than the Standard IPI for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab and CHOP (R-CHOP).

Laurie H. Sehn, MD, MPH, Mukesh Chhanabhai, MD, Catherine Fitzgerald, MD, Karamjit Gill, MD, Paul Hoskins, MD, Richard Klasa, MD, Kerry Savage, MD, Tamara Shenkier, MD, Judy Sutherland, MD, Kenneth Wilson, MD, Randy D. Gascoyne, MD, Joseph M. Connors, MD
Journal: Blood
Blood (2005) 106 (11): 492.
https://doi.org/10.1182/blood.V106.11.492.492
Published: 2005
Journal Articles

Rapid Infusion Rituximab in Combination with Steroid Containing Chemotherapy Can Be Given Safely and Substantially Reduces Resource Utilization.

Laurie H. Sehn, MD, MPH, Jane Donaldson, Allison Filewich, RN, Catherine Fitzgerald, MD, Karamjit K. Gill, MD, Nancy Runzer, RN, Barb Searle, RN, Sheila Souliere, MD, John J. Spinelli, PhD, Judy Sutherland, MD, Joseph M. Connors, MD
Journal: Blood
Blood (2004) 104 (11): 1407.
https://doi.org/10.1182/blood.V104.11.1407.1407
Published: 2004